Mike Romanos Appointed as CEO of Crescendo Biologics

CAMBRIDGE, England, January 5, 2011 - Crescendo Biologics Limited (Crescendo) today announces the
appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been
Chief Scientific Officer of the company since May 2009 and has led the
formation of the company and the development of its proprietary antibody
fragment technologies.

During this time, the company has made significant progress in
the establishment of its team and its technology platforms. This has included
the establishment of a colony of engineered mice completely devoid of
endogenous antibody polypeptides, announced in September. The proprietary
'triple knockout' mice are believed to be unique and have the immunoglobulin
heavy chain (IgH), kappa light chain and lambda light chain loci all
functionally silenced by large-scale genomic deletion.

Dr Romanos has more than 23 years' biotech and pharma industry
experience and within the last 10 years has held senior global positions
leading major parts of GlaxoSmithKline Discovery.

Clive Dix, Chairman of Crescendo said: "Today's announcement
reflects the growing maturity of Crescendo and the progress the company has
made under Mike's leadership. We have seen significant advances in the
technology platform and I am sure that with Mike now taking on the CEO
position Crescendo will deliver real value from its world class, proprietary
technology platforms and grow to become a leader in next-generation antibody
therapeutics."

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody
fragment technologies to the development of new targeted therapeutics. The
Crescendo transgenic mouse platform under development has the potential to
rapidly and predictably generate high-affinity human heavy chain antibodies
that readily yield VH fragments that have no requirement for humanisation.
This is combined with a powerful in vitro ribosome display technology which
offers significant advantages over existing approaches in antibody
optimisation. VH fragments provide great flexibility as a starting point for
the development of new targeted therapeutics combining the specificity and
binding affinity of antibodies with certain desirable characteristics of
small molecules.

Crescendo's technologies were invented by scientists at the
Babraham Institute, Cambridge (UK). The Company has raised GBP4.5 million in
seed funding from leading life sciences investors, Sofinnova Partners with
Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.
www.crescendobiologics.com

    Contacts

    Mike Romanos/Amanda Bettison
    Crescendo Biologics
    Tel: +44(0)1223-497140
    Email: mromanos/abettison@crescendobiologics.com

    Chris Gardner
    Citigate Dewe Rogerson
    Tel: +44(0)207-638-9571
    Email: chris.gardner@citigatedr.co.uk

Mike Romanos/Amanda Bettison, Crescendo Biologics, Tel: +44(0)1223-497140, Email: mromanos/abettison at crescendobiologics.com ; Chris Gardner, Citigate Dewe Rogerson, Tel: +44(0)207-638-9571, Email: chris.gardner at citigatedr.co.uk